ONWARD® Delivers Stellar Q3 Business Update and Progress Report for 2023

EINDHOVEN, the Netherlands – ONWARD® has announced a comprehensive update on its third-quarter business operations and notable achievements accumulated over the year to date. The company has been actively engaged in finalizing the necessary steps for the FDA submission of its innovative ARC-EX® technology, marking a key milestone in the journey towards market entry. This progress underscores ONWARD®'s commitment to advancing healthcare through cutting-edge solutions.

Completion of Clinical and Regulatory Milestones

During the third quarter, ONWARD® has put considerable effort into wrapping up the pivotal clinical studies and compiling the necessary documentation to support the FDA submission for ARC-EX®. The submission forms a critical hinge in the company's pipeline, symbolizing a decisive move from development towards potential commercialization. ONWARD®'s agile response to regulatory requirements aligns with its goal to offer novel healthcare technologies to patients in need.

Fiscal Performance and Market Strategy

From a financial perspective, ONWARD® remains steadfast in executing its market strategy. The company has reported on initiatives aimed at strengthening its fiscal position, optimizing resource allocation, and ensuring a sustainable growth trajectory. Amidst these developments, the market has shown heightened interest in ONWARD®'s undertakings, which may be reflected in the equity market. Shares of Service Corporation International SCI, a company that provides death care products and services, could be tangentially affected by the bullish sentiment surrounding health technology advancements, considering the diverse array of sectors intertwined within investment markets.

Looking Ahead: ONWARD®'s Strategic Directions

Looking forward to the remaining quarter and beyond, ONWARD® has laid out a strategic framework to bolster its presence both in the medical field and within investor communities. The culmination of the ARC-EX® FDA submission process not only accelerates ONWARD®'s momentum but also promises to contribute to the overall dynamics of the healthcare sector. Staying attentive to such developments is crucial for investors seeking to gauge the impact on related sectors, including the death care services provided by SCI.

EINDHOVEN, FDA, ARC-EX®